从发现到临床实施一个胰腺血液生物标志物,阿波利波蛋白A2异型的临床实施
Ayumi Kashiro1, Giman Jung2, Kazufumi Honda1,3
1Institution for Advanced Medical Science, Nippon Medical School, Tokyo, Japan.
Cancer biomarkers : section A of Disease markers
|April 2, 2025
概括
研究人员在血液中发现了特定的阿波利波蛋白A2异型 (apoA2-i),可以帮助诊断胰腺癌. 这一发现导致了在日本获得批准的用于早期检测的体外诊断套件.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 生物标志物发现发现
背景情况:
- 胰腺癌的诊断仍然具有挑战性,特别是在无症状个体中.
- 迫切需要可靠的血液生物标志物来识别高风险人群.
研究的目的:
- 审查阿波利波蛋白A2异型 (apoA2-i) 作为用于胰腺癌诊断的血液生物标志物的开发和临床验证.
- 要突出从蛋白质组发现到已批准的体外诊断 (IVD) 工具包的旅程.
主要方法:
- 蛋白质组分析以确定新的胰腺癌生物标志物.
- 开发和验证与酶相关的免疫吸收试验 (ELISA) 试剂,用于apoA2-i测量.
- 日本的多中心临床研究和监管审批流程.
主要成果:
- 在胰腺癌患者的血液中发现了apoA2-i的异常.
- 为apoA2-i开发和验证了ELISA试剂.
- 一个用于apoA2-i的IVD套件在2023年在日本获得了营销批准,并在临床实践中使用.
结论:
- ApoA2-i代表了一种有前途的血液生物标志物,用于胰腺癌诊断.
- 研究结果成功转化为临床IVD套件,表明早期检测策略取得了重大进展.
相关概念视频
01:30Acute Pancreatitis II: Clinical Manifestations and Management
75
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
75
01:29Chronic Pancreatitis II: Collaborative Care
50
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
50